文献速递肝病消化道肿瘤与早癌

成人免疫耐受期慢性乙型肝炎抗病毒治疗的成本效果

Cost-effectiveness of antiviral treatment in adult patients with immune-tolerant phase chronic hepatitis B.
PubMed 文献 · Gut · 2020-11-25

社会角度下,若肝细胞癌风险≥0.43%,立即治疗为优势策略。

要点

  • 免疫耐受期启动抗病毒治疗在20年模拟中较延迟治疗具成本效果
  • 年肝细胞癌风险≥0.54%时,医疗系统角度下立即治疗具成本效果
  • 社会角度下肝细胞癌风险≥0.43%时立即治疗为优势策略

核心结论

  • 在免疫耐受期启动抗病毒治疗相比延迟至活动性肝炎期治疗具有成本效果,尤其当肝细胞癌风险增加、药物成本降低及考虑生产力损失时。

研究设计与样本

  • Markov模型比较免疫耐受期立即治疗(treat-IT)与延迟至活动性肝炎期治疗(untreat-IT)的预期成本和质量调整生命年(QALY),时间跨度20年。
  • 模型输入参数来自韩国Asan Medical Center既往研究,计算增量成本效果比(ICER)。

主要发现

  • 社会角度下考虑早死导致的生产力损失,treat-IT策略极具成本效果;若肝细胞癌风险≥0.43%,treat-IT为优势策略(ICER<0)。
  • 对treat-IT策略成本效果影响最大的参数为肝细胞癌风险相关因素(HBV DNA水平、血小板计数和年龄)及药物成本。

关键数值与推荐

  • untreat-IT组年肝细胞癌发病率为0.73%。
  • 社会角度下,肝细胞癌风险≥0.43%时treat-IT为优势策略(ICER<0)。

临床怎么用

  • 对于免疫耐受期慢性乙肝成人患者,可考虑启动抗病毒治疗以改善长期成本效果,尤其当肝细胞癌风险较高时。
  • 决策时应综合评估肝细胞癌风险相关因素(如HBV DNA水平、血小板计数和年龄)及药物成本。
  • 从社会角度考虑生产力损失时,免疫耐受期治疗的經濟学优势更为明显。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The cost-effectiveness of antiviral treatment in adult immune-tolerant (IT) phase chronic hepatitis B (CHB) patients is uncertain. DESIGN: We designed a Markov model to compare expected costs and quality-adjusted life-years (QALYs) of starting antiviral treatment at IT-phase ('treat-IT') vs delaying the therapy until active hepatitis phase ('untreat-IT') in CHB patients over a 20-year horizon. A cohort of 10 000 non-cirrhotic 35-year-old patients in IT-phase CHB (hepatitis B e antigen-positive, mean serum hepatitis B virus (HBV) DNA levels 7.6 log10 IU/mL, and normal alanine aminotransferase levels) was simulated. Input parameters were obtained from previous studies at Asan Medical Center, Korea. The incremental cost-effectiveness ratio (ICER) between the treat-IT and untreat-IT strategies was calculated. RESULTS: From a healthcare system perspective, the treat-IT strategy with entecavir or tenofovir had an ICER of US$16 516/QALY, with an annual hepatocellular carcinoma (HCC) incidence of 0.73% in the untreat-IT group. With the annual HCC risk ≥0.54%, the treat-IT strategy was cost-effective at a willingness-to-pay threshold of US$20 000/QALY. From a societal perspective considering productivity loss by premature death, the treat-IT strategy was extremely cost-effective, and was dominant (ICER <0) if the HCC risk was ≥0.43%, suggesting that the treat-IT strategy incurs less costs than the untreat-IT strategy. The most influential parameters on cost-effectiveness of the treat-IT strategy were those related with HCC risk (HBV DNA levels, platelet counts and age) and drug cost. CONCLUSION: Starting antiviral therapy in IT phase is cost-effective compared with delaying the treatment until the active hepatitis phase in CHB patients, especially with increasing HCC risk, decreasing drug costs and consideration of productivity loss.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Kim HL, Kim GA, Park JA, et al. Cost-effectiveness of antiviral treatment in adult patients with immune-tolerant phase chronic hepatitis B. Gut. 2020. PMID: 33239344. doi:10.1136/gutjnl-2020-321309

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。